172 related articles for article (PubMed ID: 24934485)
21. Novel oncogene and tumor suppressor mutations in KIT and PDGFRA wild type gastrointestinal stromal tumors revealed by next generation sequencing.
Hechtman JF; Zehir A; Mitchell T; Borsu L; Singer S; Tap W; Oultache A; Ladanyi M; Nafa K
Genes Chromosomes Cancer; 2015 Mar; 54(3):177-84. PubMed ID: 25427437
[TBL] [Abstract][Full Text] [Related]
22. Clinicopathological correlates and prognostic significance of KRAS mutation status in a pooled prospective cohort of epithelial ovarian cancer.
Nodin B; Zendehrokh N; Sundström M; Jirström K
Diagn Pathol; 2013 Jun; 8():106. PubMed ID: 23800114
[TBL] [Abstract][Full Text] [Related]
23. Molecular characterization of PDGFR-alpha/PDGF-A and c-KIT/SCF in gliosarcomas.
Reis RM; Martins A; Ribeiro SA; Basto D; Longatto-Filho A; Schmitt FC; Lopes JM
Cell Oncol; 2005; 27(5-6):319-26. PubMed ID: 16373964
[TBL] [Abstract][Full Text] [Related]
24. High resolution melting analysis for rapid and sensitive EGFR and KRAS mutation detection in formalin fixed paraffin embedded biopsies.
Do H; Krypuy M; Mitchell PL; Fox SB; Dobrovic A
BMC Cancer; 2008 May; 8():142. PubMed ID: 18495026
[TBL] [Abstract][Full Text] [Related]
25. Spectrum of somatic EGFR, KRAS, BRAF, PTEN mutations and TTF-1 expression in Brazilian lung cancer patients.
Carneiro JG; Couto PG; Bastos-Rodrigues L; Bicalho MA; Vidigal PV; Vilhena A; Amaral NF; Bale AE; Friedman E; De Marco L
Genet Res (Camb); 2014; 96():e002. PubMed ID: 24594201
[TBL] [Abstract][Full Text] [Related]
26. [Clinicopathologic characteristics of head and neck carcinoma showing thymus-like element].
Cui XJ; Zhang CY; Su P; Lyu B; Ren YB; Fan XS; Zhang XF; Wang Y; Song YH; Liu ZY
Zhonghua Bing Li Xue Za Zhi; 2017 Mar; 46(3):155-159. PubMed ID: 28297754
[No Abstract] [Full Text] [Related]
27. Epidermal growth factor receptor and KRAS mutations in lung adenocarcinoma: a retrospective study of the Lebanese population.
Fakhruddin N; Mahfouz R; Farhat F; Tfayli A; Abdelkhalik R; Jabbour M; Yehia L; Mahfoud Z; Zaatari G
Oncol Rep; 2014 Nov; 32(5):2223-9. PubMed ID: 25120214
[TBL] [Abstract][Full Text] [Related]
28. Gene mutations in small-cell lung cancer (SCLC): results of a panel of 6 genes in a cohort of Italian patients.
Bordi P; Tiseo M; Barbieri F; Bavieri M; Sartori G; Marchetti A; Buttitta F; Bortesi B; Ambrosini-Spaltro A; Gnetti L; Silini EM; Ardizzoni A; Rossi G
Lung Cancer; 2014 Dec; 86(3):324-8. PubMed ID: 25453846
[TBL] [Abstract][Full Text] [Related]
29. Tyrosine kinase receptor status in endometrial stromal sarcoma: an immunohistochemical and genetic-molecular analysis.
Cossu-Rocca P; Contini M; Uras MG; Muroni MR; Pili F; Carru C; Bosincu L; Massarelli G; Nogales FF; De Miglio MR
Int J Gynecol Pathol; 2012 Nov; 31(6):570-9. PubMed ID: 23018215
[TBL] [Abstract][Full Text] [Related]
30. The prognostic values of EGFR expression and KRAS mutation in patients with synchronous or metachronous metastatic colorectal cancer.
Huang CW; Tsai HL; Chen YT; Huang CM; Ma CJ; Lu CY; Kuo CH; Wu DC; Chai CY; Wang JY
BMC Cancer; 2013 Dec; 13():599. PubMed ID: 24330663
[TBL] [Abstract][Full Text] [Related]
31. The clinicopathological significance of ALK rearrangements and KRAS and EGFR mutations in primary pulmonary mucinous adenocarcinoma.
Qu Y; Che N; Zhao D; Zhang C; Su D; Zhou L; Zhang L; Wang C; Zhang H; Wei L
Tumour Biol; 2015 Aug; 36(8):6417-24. PubMed ID: 25813151
[TBL] [Abstract][Full Text] [Related]
32. Cytomorphologic features of advanced lung adenocarcinomas tested for EGFR and KRAS mutations: a retrospective review of 50 cases.
Marotti JD; Schwab MC; McNulty NJ; Rigas JR; DeLong PA; Memoli VA; Tsongalis GJ; Padmanabhan V
Diagn Cytopathol; 2013 Jan; 41(1):15-21. PubMed ID: 21681971
[TBL] [Abstract][Full Text] [Related]
33. Analysis of mutation and expression of c-kit and PDGFR-alpha gene in gastrointestinal stromal tumor.
Zheng S; Chen LR; Wang HJ; Chen SZ
Hepatogastroenterology; 2007 Dec; 54(80):2285-90. PubMed ID: 18265649
[TBL] [Abstract][Full Text] [Related]
34. Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial.
Tabernero J; Lenz HJ; Siena S; Sobrero A; Falcone A; Ychou M; Humblet Y; Bouché O; Mineur L; Barone C; Adenis A; Yoshino T; Goldberg RM; Sargent DJ; Wagner A; Laurent D; Teufel M; Jeffers M; Grothey A; Van Cutsem E
Lancet Oncol; 2015 Aug; 16(8):937-48. PubMed ID: 26184520
[TBL] [Abstract][Full Text] [Related]
35. Individualized therapies in colorectal cancer: KRAS as a marker for response to EGFR-targeted therapy.
Chang DZ; Kumar V; Ma Y; Li K; Kopetz S
J Hematol Oncol; 2009 Apr; 2():18. PubMed ID: 19386128
[TBL] [Abstract][Full Text] [Related]
36. Mutational Profile and New IASLC/ATS/ERS Classification Provide Additional Prognostic Information about Lung Adenocarcinoma: A Study of 125 Patients from Brazil.
de Melo AC; Karen de Sá V; Sternberg C; Olivieri ER; Werneck da Cunha I; Fabro AT; Carraro DM; de Barros e Silva MJ; Pimenta Inada HK; de Mello ES; Soares FA; Takagaki T; Ferreira CG; Capelozzi VL
Oncology; 2015; 89(3):175-86. PubMed ID: 25833149
[TBL] [Abstract][Full Text] [Related]
37. A comparison of EGFR and KRAS status in primary lung carcinoma and matched metastases.
Monaco SE; Nikiforova MN; Cieply K; Teot LA; Khalbuss WE; Dacic S
Hum Pathol; 2010 Jan; 41(1):94-102. PubMed ID: 19740513
[TBL] [Abstract][Full Text] [Related]
38. Rare oncogenic mutations of predictive markers for targeted therapy in triple-negative breast cancer.
Grob TJ; Heilenkötter U; Geist S; Paluchowski P; Wilke C; Jaenicke F; Quaas A; Wilczak W; Choschzick M; Sauter G; Lebeau A
Breast Cancer Res Treat; 2012 Jul; 134(2):561-7. PubMed ID: 22610646
[TBL] [Abstract][Full Text] [Related]
39. Adrenal cortical neoplasms: a study of clinicopathological features related to epidermal growth factor receptor gene status.
Zhang J; Wang C; Gao J; Sun J; Zeng X; Wu S; Liang Z
Diagn Pathol; 2014 Jan; 9():19. PubMed ID: 24457059
[TBL] [Abstract][Full Text] [Related]
40. Epidermal growth factor receptor overexpression is a marker for adverse pathologic features in papillary thyroid carcinoma.
Fisher KE; Jani JC; Fisher SB; Foulks C; Hill CE; Weber CJ; Cohen C; Sharma J
J Surg Res; 2013 Nov; 185(1):217-24. PubMed ID: 23746767
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]